IMPORTANT: All tour prices, taxes, and airfares quoted in this brochure are based on tariffs, costs and United
States dollar exchange rates that were in effect at the time of publication.
All tour prices, taxes, and airfares quoted in this brochure are based on tariffs, costs, and United
States dollar exchange rates that were in effect at the time of publication.
Not exact matches
As such, changes in fair value are recognized in income, including fluctuations due to the
exchange rate between the New Taiwan
Dollar and the United
States Dollar.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for
state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and
state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign
exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
exchange rate of the U.S.
dollar that may cause an unfavorable foreign currency
exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and
Exchange Commission (t
Exchange Commission (the SEC).
Monetizing deficits has never been more attractive for the United
States, which today benefits from its foreign lenders» willingness to be repaid in US funds, putting them at the mercy of the US
dollar exchange rate.
The Plaza Accord is a 1985 agreement among the G - 5 nations (France, Germany, the United
States, the United Kingdom and Japan) to manipulate
exchange rates by depreciating the U.S.
dollar relative to the Japanese yen and the German Deutsche mark.
The yen /
dollar exchange rate could also be further impacted by the announcement of third - quarter United
States GDP growth.
It is now June, and Jemery's Steelworks are worrying about what the
exchange rate will be in January when they must convert Canadian
dollars to United
States dollars to pay for the shipment.
The measure would create a marketplace
exchange that ostensibly would bring down insurance
rates and free up millions of
dollars in federal aid to the
state.
The factional NLC leader
stated, was demanding N90, 000 national minimum wage based on the current
exchange rate, noting that should the
exchange rate go above N500 per
dollar, NLC would demand for more than N90, 000.
For example, if the sale currency is in Euros and the payment currency is US
Dollars, nowhere does it
state it will use any sort of known foreign currency
exchange rate (such as Forex or OANDA).
54 - 105, 1954 - 1 C.B. 12,
states that for purposes of determining gain, the basis and selling price of property acquired by a U.S. citizen living in a foreign country should be expressed in United States dollars at the rates of exchange prevailing as of the dates of purchase and sale of the property, respect
states that for purposes of determining gain, the basis and selling price of property acquired by a U.S. citizen living in a foreign country should be expressed in United
States dollars at the rates of exchange prevailing as of the dates of purchase and sale of the property, respect
States dollars at the
rates of
exchange prevailing as of the dates of purchase and sale of the property, respectively.
Following the United
States» measures to devalue the
dollar in the summer of 1971, the Japanese government agreed to a new, fixed
exchange rate as part of the Smithsonian Agreement, signed at the end of the year.
ECONOMIC OVERVIEW Currency: Australian
Dollar ($ A) Market
Exchange Rate (5/24/02): US $ 1 = $ A1.79 Nominal Gross Domestic (GDP, 2001E): U.S. $ 365.8 billion Real GDP Growth
Rate (2001E): 4.1 % (2002F): 3.8 % Inflation
Rate (2001E): 4.3 % (2002F): 3.0 % Unemployment
Rate (2001E): 6.9 % (2002F): 7.0 % Current Account Balance (2001E): - $ 15.3 billion (2002F): - $ 16.9 billion Major Trading Partners: Japan, other Far East, European Union, United
States Major Export Products: crude materials, food and live animals, mineral fuels and lubricants Major Import Products: machinery and transport equipment, manufactured goods, chemicals
Amidst negative rumours about Tether, the US - based cryptocurrency
exchange Bittrex published a notice
stating it will list a stable coin tied to the US
dollar rate.
Sales commission report updates and
exchange rate conversion for Sales Report By
State from Euros to US
dollars.